Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223) by SeagenPortfolio reprioritization and extension of cash runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, Aug. 22, 2023 (GLOBE NEWSWIRE) LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody
Shares of LAVA Therapeutics N.V. (LVTX) were up 61% on Friday on clinical development by Janssen Biotech to support the development of cancer treatment. LVTX is trading on Nasdaq at $3.
UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2023 (GLOBE NEWSWIRE) LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on.
Through a research collaboration with Janssen, a lead candidate was identified for further development towards clinical studies.In May 2020, LAVA entered.